

Rachelle Lanciano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/502985/publications.pdf>

Version: 2024-02-01

72
papers

3,158
citations

147801

31
h-index

149698

56
g-index

72
all docs

72
docs citations

72
times ranked

2942
citing authors

#	ARTICLE	IF	CITATIONS
1	The patterns of care outcome study for cancer of the uterine cervix results of the second national practice survey. <i>Cancer</i> , 1990, 66, 2451-2456.	4.1	191
2	Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma. <i>Cancer</i> , 2008, 112, 1954-1963.	4.1	177
3	Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 27, 825-830.	0.8	175
4	Randomized Comparison of Weekly Cisplatin or Protracted Venous Infusion of Fluorouracil in Combination With Pelvic Radiation in Advanced Cervix Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 8289-8295.	1.6	168
5	Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis. <i>Journal of Clinical Oncology</i> , 1994, 12, 510-515.	1.6	152
6	Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry. <i>Radiation Oncology</i> , 2018, 13, 26.	2.7	142
7	Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 2136-2142.	1.6	135
8	Inaccuracies in using the lumpectomy scar for planning electron boosts in primary breast carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 43-48.	0.8	129
9	Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. <i>Cancer</i> , 1993, 71, 3697-3702.	4.1	124
10	Influence of age, prior abdominal surgery, fraction size, and dose on complications after radiation therapy for squamous cell cancer of the uterine cervix. A patterns of care study. <i>Cancer</i> , 1992, 69, 2124-2130.	4.1	116
11	Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma?. <i>Gynecologic Oncology</i> , 2007, 105, 427-433.	1.4	86
12	Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation. <i>Gynecologic Oncology</i> , 2014, 135, 208-212.	1.4	85
13	The results of radiotherapy for orbital pseudotumor. <i>International Journal of Radiation Oncology Biology Physics</i> , 1990, 18, 407-411.	0.8	72
14	Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 63-70.	0.7	70
15	Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry™s experience. <i>Radiation Oncology</i> , 2017, 12, 35.	2.7	68
16	Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: Accuracy and reproducibility. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 111-118.	0.8	61
17	Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 42, 43-50.	0.8	54
18	The Relationship of Local and Distant Failure from Endometrial Cancer: Defining a Clinical Paradigm. <i>Gynecologic Oncology</i> , 1997, 66, 411-416.	1.4	52

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of CA 19-9 Levels in Patients with Carcinoma of the Pancreas Treated With Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 393-396.	0.8	52
20	Improved Treatment Planning for the Syed-Neblett Template Using Endorectal-Coil Magnetic Resonance and Intraoperative (Laparotomy/Laparoscopy) Guidance: A New Integrated Technique for Hysterectomized Women with Vaginal Tumors. <i>Gynecologic Oncology</i> , 1995, 56, 255-261.	1.4	50
21	Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 1990, 39, 368-373.	1.4	46
22	Surgical complications of intraoperative radiation therapy: The radiation therapy oncology group experience. <i>Journal of Surgical Oncology</i> , 1992, 50, 209-215.	1.7	46
23	A reappraisal of the international federation of gynecology and obstetrics staging system for cervical cancer. A study of patterns of care. <i>Cancer</i> , 1992, 69, 482-487.	4.1	45
24	The Efficacy and Safety of Once-Daily Kytril [®] (Granisetron Hydrochloride) Tablets in the Prophylaxis of Nausea and Emesis Following Fractionated Upper Abdominal Radiotherapy. <i>Cancer Investigation</i> , 2001, 19, 763-772.	1.3	45
25	Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses. <i>Journal of Radiation Oncology</i> , 2015, 4, 65-70.	0.7	44
26	Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors. <i>Frontiers in Oncology</i> , 2012, 2, 23.	2.8	43
27	The justification for a surgical staging system in endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 1993, 28, 189-196.	0.6	41
28	A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 287-292.	1.1	41
29	Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2010, 117, 270-275.	1.4	39
30	Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience. <i>Frontiers in Oncology</i> , 2015, 5, 106.	2.8	34
31	Red Shell: Defining a High-Risk Zone of Normal Tissue Damage in Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 903-909.	0.8	33
32	Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011, 121, 542-545.	1.4	33
33	Postoperative radiation therapy for surgically staged endometrial cancer: Impact of time factors (overall treatment time and surgery-to-radiation interval) on outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 837-842.	0.8	32
34	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. <i>Gynecologic Oncology</i> , 2016, 143, 294-301.	1.4	31
35	Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: A phase II study from radiation therapy oncology group 85-04. <i>Annals of Surgical Oncology</i> , 1995, 2, 295-302.	1.5	29
36	Intra- and Perioperative Complications Associated with Tandem and Colpostat Application for Cervix Cancer. <i>Gynecologic Oncology</i> , 1997, 64, 224-229.	1.4	29

#	ARTICLE	IF	CITATIONS
37	Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 249.	2.8	27
38	The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: Analysis of 32 cases. <i>Obstetrics and Gynecology</i> , 1995, 86, 955-959.	2.4	26
39	SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines. <i>Frontiers in Oncology</i> , 2014, 4, 312.	2.8	26
40	Retrospective Analysis of Concomitant Cisplatin During Radiation in Patients Aged 55 Years or Older for Treatment of Advanced Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1258-1263.	2.5	26
41	Perioperative morbidity of intracavitary gynecologic brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 29, 969-974.	0.8	25
42	Optimizing radiation parameters for cervical cancer. <i>Seminars in Radiation Oncology</i> , 2000, 10, 36-43.	2.2	23
43	Wound complications after resection and immediate postoperative brachytherapy in the management of soft-tissue sarcomas. <i>Annals of Surgical Oncology</i> , 1996, 3, 51-56.	1.5	22
44	Phase II Trial of Preoperative Chemoradiation With a Hyperfractionated Radiation Boost in Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 435-441.	1.3	19
45	Adjuvant Treatment for Endometrial Cancer: Who Needs It?. <i>Gynecologic Oncology</i> , 1995, 57, 135-137.	1.4	18
46	Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 283.e1-283.e7.	1.3	17
47	The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups. <i>Frontiers in Oncology</i> , 2016, 6, 184.	2.8	17
48	SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 101.	2.8	15
49	Over 20 years of progress in radiation oncology: Cervical cancer. <i>Seminars in Radiation Oncology</i> , 1997, 7, 121-126.	2.2	14
50	Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting. <i>Frontiers in Oncology</i> , 2015, 5, 146.	2.8	13
51	Effect of Fractionation in Stereotactic Body Radiation Therapy Using the Linear Quadratic Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 150-156.	0.8	12
52	CURRENT DEVELOPMENTS IN THE TREATMENT OF NEWLY DIAGNOSED CERVICAL CANCER. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 275-303.	2.2	11
53	Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database. <i>Frontiers in Oncology</i> , 2017, 7, 185.	2.8	11
54	Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer. <i>Journal of Radiation Oncology</i> , 2016, 5, 187-195.	0.7	10

#	ARTICLE	IF	CITATIONS
55	Repeat Thoracic Stereotactic Body Radiation Therapy (SBRT) for Nonsmall Cell Lung Cancer: Long-Term Outcomes, Toxicity, and Dosimetric Considerations. <i>Advances in Radiation Oncology</i> , 2020, 5, 984-993.	1.2	9
56	Volume effects in radiosurgical spinal cord dose tolerance: how small is too small?. <i>Journal of Radiation Oncology</i> , 2019, 8, 53-61.	0.7	8
57	CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 652646.	2.8	7
58	Combined modality treatment for carcinomas of the uterine cervix and vulva. <i>Current Opinion in Oncology</i> , 1994, 6, 524-530.	2.4	6
59	Intraoperative liver radiation after partial hepatectomy in a rat model. <i>Journal of Surgical Research</i> , 1992, 53, 287-292.	1.6	5
60	A "Red Shell" concept of increased radiation damage hazard to normal tissues just outside the PTV target volume. <i>Radiotherapy and Oncology</i> , 2010, 94, 384.	0.6	5
61	The effect of whole-brain radiation (WBI) and Karnofsky performance status (KPS) on survival of patients receiving stereotactic radiosurgery (SRS) for second brain metastatic event. <i>Journal of Radiation Oncology</i> , 2017, 6, 31-37.	0.7	4
62	Single Institutional Experience of Stereotactic Radiosurgery Alone for First Brain Metastatic Event and Salvage of Second Brain Metastatic Event in a Community Setting with Review of the Literature. <i>Frontiers in Oncology</i> , 2017, 7, 32.	2.8	3
63	Treatment-Related Myelodysplastic Syndrome Following Abdominopelvic Radiotherapy for Endometrial Cancer. <i>Gynecologic Oncology</i> , 1995, 57, 430-432.	1.4	2
64	OPTIMIZING RADIATION TREATMENT FOR CERVICAL CANCER. <i>Surgical Clinics of North America</i> , 2001, 81, 859-870.	1.5	2
65	Clinical evidence for dose tolerance of the central nervous system in hypofractionated radiotherapy. <i>Journal of Radiation Oncology</i> , 2018, 7, 293-305.	0.7	2
66	Radiation therapy for gynecologic cancer. <i>Current Opinion in Oncology</i> , 1990, 2, 885-892.	2.4	1
67	Radiotherapy for gynecologic malignancies. <i>Current Opinion in Oncology</i> , 1992, 4, 930-938.	2.4	1
68	37 The relationship of local and distant failure from endometrial cancer: Defining a clinical paradigm. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 36, 177.	0.8	1
69	2047 Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 36, 301.	0.8	0
70	2102 The effect of adjuvant megace on outcome for stage III endometrial carcinoma: A multivariate analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 36, 327.	0.8	0
71	Predictors of long-term survival for localized prostate cancer treated with high-dose IMRT stratified by NCCN 2015 guidelines in a community hospital setting. <i>Journal of Radiation Oncology</i> , 2016, 5, 95-101.	0.7	0
72	Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up. <i>Frontiers in Oncology</i> , 2020, 10, 1505.	2.8	0